- Home
- RDIB vs ACTU Comparison
RDIB vs ACTU Comparison
Compare RDIB & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- ACTU
- Stock Information
- Founded
- RDIB 1937
- ACTU 2015
- Country
- RDIB United States
- ACTU United States
- Employees
- RDIB N/A
- ACTU N/A
- Industry
- RDIB Movies/Entertainment
- ACTU
- Sector
- RDIB Consumer Discretionary
- ACTU
- Exchange
- RDIB Nasdaq
- ACTU NYSE
- Market Cap
- RDIB 140.2M
- ACTU 135.0M
- IPO Year
- RDIB N/A
- ACTU 2024
- Fundamental
- Price
- RDIB $9.51
- ACTU $7.47
- Analyst Decision
- RDIB
- ACTU Strong Buy
- Analyst Count
- RDIB 0
- ACTU 1
- Target Price
- RDIB N/A
- ACTU $20.00
- AVG Volume (30 Days)
- RDIB 6.7K
- ACTU 85.1K
- Earning Date
- RDIB 08-13-2025
- ACTU 05-15-2025
- Dividend Yield
- RDIB N/A
- ACTU N/A
- EPS Growth
- RDIB N/A
- ACTU N/A
- EPS
- RDIB N/A
- ACTU N/A
- Revenue
- RDIB $205,644,000.00
- ACTU N/A
- Revenue This Year
- RDIB $7.47
- ACTU N/A
- Revenue Next Year
- RDIB $13.22
- ACTU N/A
- P/E Ratio
- RDIB N/A
- ACTU N/A
- Revenue Growth
- RDIB N/A
- ACTU N/A
- 52 Week Low
- RDIB $5.78
- ACTU $5.51
- 52 Week High
- RDIB $21.34
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- RDIB 45.18
- ACTU N/A
- Support Level
- RDIB $9.00
- ACTU N/A
- Resistance Level
- RDIB $12.72
- ACTU N/A
- Average True Range (ATR)
- RDIB 1.33
- ACTU 0.00
- MACD
- RDIB -0.12
- ACTU 0.00
- Stochastic Oscillator
- RDIB 19.13
- ACTU 0.00
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.